Close Menu

In an effort to speed up the drug discovery process for multi-drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis, UCSD's Philip Bourne led work that used a proteomic, computational approach to identify cross-reactivity between different drug target families. The team showed that entacapone and tolcapone, two drugs used to treat Parkinson's disease, can also help treat MDR and XDR tuberculosis. The work appears in PLoS Computational Biology this week.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.